MSOX Falls -25% in 30 Days: Navigating the Leveraged Cannabis ETF

Key Takeaways

• MSOX declined roughly 25% over the trailing 30 days, reflecting leveraged exposure to a sharp drawdown in U.S. cannabis equities.
• The selloff was triggered by a procedural pause in federal cannabis rescheduling proceedings, resetting the timeline for a potential Schedule III classification.
• As a 2x daily leveraged fund, MSOX seeks double the daily return of the AdvisorShares Pure US Cannabis ETF (MSOS) and amplifies both gains and losses.
• Underlying exposure is concentrated in U.S. multi-state operators, led by Trulieve, Green Thumb Industries, and Curaleaf.
• Over the trailing quarter the fund was down roughly 21%, extending a volatile, headline-driven trend.
• Federal rescheduling and Section 280E tax relief remain the dominant catalysts for the fund's direction.

Understanding the AdvisorShares MSOS 2x Daily ETF

The AdvisorShares MSOS 2x Daily ETF is an actively managed leveraged exchange-traded fund that seeks daily investment results corresponding to approximately two times the daily total return of the AdvisorShares Pure US Cannabis ETF (MSOS), before fees and expenses. It achieves this exposure primarily through total return swap agreements rather than holding the underlying stocks directly. Launched in August 2022, the fund carries a net expense ratio of approximately 0.95% and is classified as non-diversified, with assets under management in the modest range of roughly $40–50 million.

Because MSOS focuses on U.S. cannabis multi-state operators, MSOX's effective exposure stays narrow as well. The largest underlying names include Trulieve, Green Thumb Industries, Curaleaf, Verano, and Cresco Labs. This concentration, paired with daily 2x leverage, makes the fund highly sensitive to cannabis-specific news and capable of sharp moves in short periods. I also checked this using Tickeron’s AI Screener to see how the fund compares to others in the industry.

Recent Price Performance: 30 Days and the Quarter

Over the trailing 30 days, MSOX fell from roughly $2.37 to near $1.78, a decline of approximately 25%. The move was not gradual; much of the damage occurred in a single elevated-volume session in late September, followed by continued drift lower through October as the sector absorbed the policy setback. The trailing three-month performance tells a similar story. Measured against a level near $2.25 three months earlier, the fund was down approximately 21%. The pattern has been trend-driven and volatile rather than range-bound, which is consistent with a leveraged instrument tracking a headline-sensitive sector.

What Moved the Fund in the Last 30 Days

The primary catalyst was regulatory. In late September, a Drug Enforcement Administration administrative law judge paused the proceedings to move cannabis from Schedule I to Schedule III, citing a Government Accountability Office report. The pause pushed a potential final decision timeline into the following year, rattling investors who had priced in near-term reform. The reaction in the underlying basket was severe. MSOS, which MSOX tracks at 2x daily leverage, fell sharply, while major holdings sold off broadly—Trulieve dropped by a double-digit percentage, and Curaleaf and Green Thumb Industries also declined. Because MSOX resets its leverage daily, these losses compounded, and the fund's 30-day decline roughly doubled the move in the underlying cannabis complex. The drawdown reflects the sector's dependence on federal policy milestones. Rescheduling to Schedule III would relieve operators of the Section 280E tax burden, which currently prevents cannabis companies from deducting ordinary business expenses and pushes effective tax rates well above typical corporate levels.

Performance Drivers Over the Last Quarter

The broader three-month trend was shaped by a sequence of policy headlines and industry consolidation. Earlier in the period, optimism around the landmark move to reclassify medical cannabis from Schedule I to Schedule III supported a rebound in cannabis equities, helping lift MSOX from summer lows into September. That momentum reversed once the DEA procedural pause cast doubt on the timeline. Sector-specific merger activity—including Curaleaf's unsolicited pursuit of Canadian operator Aurora Cannabis—and Trulieve's milestone as the first U.S. plant-touching operator to list on the New York Stock Exchange (TRLV) added to a choppy, sentiment-driven tape. For a daily-leveraged fund, this combination of sharp rallies and drawdowns creates meaningful volatility drag, which can cause longer-horizon returns to diverge from two times the underlying index's cumulative return.

Key Factors to Watch Going Forward

The most important factor ahead is the federal rescheduling timeline. Any clarification on whether the DEA reopens the record, grants additional briefings, or advances the Schedule III process will likely drive the underlying basket—and, through leverage, MSOX—in either direction. Investors should also monitor Section 280E developments, since permanent tax relief would materially improve the cash flow and earnings profiles of multi-state operators. Beyond policy, capital flows into the cannabis sector, continued consolidation among operators, state-level retail expansion, and the earnings trajectory of Trulieve, Green Thumb Industries, and Curaleaf will shape the outlook. Risks include further procedural delays, valuation pressure, and the structural reality of leveraged fund decay during sustained volatility. These themes, rather than short-term headlines, are likely to define MSOX's path over the coming months. From what I see, this remains a sector where policy clarity will matter most.

Exploring Tickeron’s AI Tools for Research

In my own analysis of leveraged products like MSOX, I often turn to Tickeron’s AI Screener to quickly scan for comparable volatility patterns and sector exposure. The platform lets me filter by technical indicators, fundamentals, and AI-generated signals, which helps put short-term moves into better context without manual effort. It has become a regular part of how I review names in volatile areas such as cannabis. The tool surfaces breakout candidates and industry themes efficiently, supporting a more structured approach to research.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Industry description